July 09, 2026 16:05 ET | Source: Option Care Health, Inc.
BANNOCKBURN, Ill., July 09, 2026 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2026 on Wednesday, July 29, 2026 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day.
Conference Call Details
Participants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BI808c970d451b4e5ba580364e7e07d20a. The call can also be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
For Investor Inquiries:
Bob Okunski
Vice President, Investor Relations [email protected]
New York, New York--(Newsfile Corp. - May 11, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Option Care Health, Inc. (NASDAQ: OPCH) ("Option Care Health, Inc.") concerning potential violations of the federal securities laws.
The Q1 2026 earnings report revealed a revenue shortfall against analyst expectations. The Company simultaneously reduced its FY 2026 revenue guidance by up to 3.75% -- a cut of as much as $225 million from the top end of its prior range. The revised outlook of $5.675 billion-$5.775 billion represented a sharp departure from the $5.8 billion-$6.0 billion range that CEO John Rademacher and CFO Meenal Sethna had reaffirmed just 65 days earlier on the Q4 2025 earnings call on February 24, 2026.
The Company cited increased headwinds from the Stelara biosimilar conversion as a contributing factor. On February 24, 2026, CFO Sethna had quantified this headwind at $25 million-$35 million for FY 2026. By April 30, the headwind had increased to $55 million, as "the number of Stelara patients converting to some other therapy" was below expectations, leading to a drop in census and revenue expectations. The projected "400 basis point revenue growth headwind" had quickly jumped to "600 basis points" of CID portfolio headwinds.
If you suffered a loss on your Option Care Health, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004 [email protected]
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296864
On May 7, 2026, Timothy P. Sullivan, Director at Option Care Health (OPCH 2.81%), reported an open-market purchase of 24,154 shares at a weighted-average price of $20.69 per share according to the SEC Form 4 filing.
Transaction summaryMetricValueShares traded24,154Transaction value~$500,000Post-transaction shares (direct)73,383Post-transaction value (direct ownership)~$1.52 millionTransaction value based on SEC Form 4 weighted average purchase price ($20.69); post-transaction value based on May 7, 2026 market close ($20.75).
Key questionsHow does this transaction affect Sullivan’s overall ownership?
This purchase increased Sullivan’s direct holdings by 49.06%, bringing his total direct position to 73,383 shares, with no indirect or derivative holdings reported post-transaction.What is the context of this buy compared to Sullivan’s recent trading activity?
Sullivan’s last reported trade was an open-market purchase of 20,000 shares in August 2025, and this latest acquisition marks the second consecutive period of accumulation after a large sale in August 2024.How does the transaction value compare to Sullivan’s remaining holdings?
The ~$500,000 purchase represents a substantial commitment, with the post-transaction direct holdings valued at approximately ~$1.52 million at the May 7, 2026 market close.What market context surrounded this purchase?
Option Care Health shares have declined 37.9% over the past year (as of May 7, 2026), meaning Sullivan’s increased exposure is occurring at a lower price point compared to prior periods.Company overviewMetricValueRevenue (TTM)$5.67 billionNet income (TTM)$206.19 millionPrice (as of market close 5/7/26)$20.751-year price changeN/A* 1-year price change calculated using May 7th, 2026 as the reference date.
Company snapshotProvides home and alternate site infusion therapies, including anti-infective, immunoglobulin, parenteral and enteral nutrition, and specialty treatments for chronic and acute conditions.Operates a service-based model, generating revenue through clinical care, pharmaceutical dispensing, and nursing services for patients requiring complex infusion therapy outside traditional hospital settings.Serves patients with chronic and acute illnesses, hospitals, physicians, and payers across the United States, focusing on individuals needing ongoing infusion and specialty care.Option Care Health provides home and alternate site infusion services in the United States, has a national footprint, and employs approximately 8,000 people. The company leverages clinical expertise and a broad therapy portfolio to deliver high-touch, cost-effective care for patients with complex medical needs. Its scale, service breadth, and integrated care approach position it as a key partner for healthcare providers and payers seeking quality outcomes in alternate site care delivery.
What this transaction means for investorsThe Form 4 checkbox for a 10b5-1 plan is blank, which matters here. Sullivan's purchase is discretionary — he decided to buy roughly $500,000 worth of OPCH shares on May 7 without a pre-scheduled plan behind it. That carries more signal than a routine plan execution, which is essentially just following prior instructions on a timer. The pattern adds context. Sullivan sold in August 2024, then bought in August 2025, and now again this month. He's rebuilt his stake and then some across two consecutive open-market purchases — and each one has been a deliberate decision, not an automatic one. OPCH has dropped about 38% over the past year, so Sullivan is adding at a meaningfully lower price than prior transactions. Directors don't have the same real-time operational visibility that executives do, but they do sit in the boardroom. Whether insider buying registers in your own process is a personal call — but before it does, the more important thing to watch is whether the company can re-accelerate revenue growth. The CEO flagged it as the central problem last quarter, and EBITDA is already compressing. The insider signal is cleaner than most; the underlying business story still needs to prove itself.
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On.
Option Care Health executives reaffirmed $5.8B-$6.0B revenue guidance on February 24, 2026, then slashed the range to $5.675B-$5.775B just 65 days later -- a reduction of up to 3.75%.
, /PRNewswire/ -- Shareholders who held Option Care Health (NASDAQ: OPCH) watched nearly 30% of their investment vanish after the company disclosed Q1 2026 results that missed revenue expectations and cut FY 2026 guidance by as much as $225 million from the top of the previously stated range. Those who lost money on OPCH are encouraged to submit their information to Levi & Korsinsky . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
On February 24, 2026, during the Q4 2025 earnings call, CFO Meenal Sethna told investors: "We are reaffirming the guidance we announced in January. We expect full-year 2026 revenue of $5.8 billion to $6 billion." CEO John Rademacher added: "We are confident in the guidance we are putting forth and look forward to continuing our track record of execution." On April 30, 2026 -- just 65 days later -- the company revised FY 2026 revenue guidance downward to $5.675 billion to $5.775 billion, a shortfall of up to $225 million from the prior ceiling.
The February reaffirmation came with a disclosed Stelara biosimilar gross-profit headwind of $25 million to $35 million, with a 400-basis-point revenue growth headwind. The April revision instead attributed "a negative 600 basis point revenue growth headwind … due to the lower CID patient retention and therapy mix." Levi & Korsinsky is investigating whether Option Care Health's prior guidance statements adequately reflected information available to management at the time they were made.
OPCH investors who suffered losses are encouraged to contact Levi & Korsinsky to discuss their legal rights . You may also reach Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
Frequently Asked Questions About the OPCH Investigation
Q: Who is conducting the OPCH investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased OPCH securities and suffered financial losses. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Option Care Health made materially false or misleading statements regarding its FY 2026 revenue guidance. On February 24, 2026, management reaffirmed a $5.8 billion to $6.0 billion revenue range. On April 30, 2026, the company reduced that range to $5.675 billion to $5.775 billion -- a reduction of up to 3.75%.
Q: How much did OPCH stock drop? A: Shares fell approximately 26.4% by market open on April 30, 2026, after the company reported a Q1 revenue miss and slashed FY 2026 guidance. Investors who purchased shares at higher prices may have sustained significant losses.
Q: What do OPCH investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What if I already sold my OPCH shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OPCH and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Option Care Health stock drops nearly 30% on April 30, 2026, after the company reports a Q1 revenue miss and slashes FY 2026 guidance by up to 3.75% May 14, 2026 09:00 ET | Source: Levi & Korsinsky, LLP
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Option Care Health (NASDAQ: OPCH) shares fell approximately 26.4% by market open and achieved losses of more than 30% at midday following the Company’s Q1 2026 report which disclosed a significant revenue miss below Wall Street expectations and a significant cut to the company’s full-year 2026 revenue guidance from $5.8 billion-$6.0 billion down to $5.675 billion-$5.775 billion. Shareholders who lost money on their OPCH investment are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP has initiated an investigation into whether Option Care Health made materially false or misleading statements to investors. On the company's Q4 2025 earnings call on February 24, 2026, CFO Meenal Sethna stated: "We are reaffirming the guidance we announced in January. We expect full-year 2026 revenue of $5.8 billion to $6 billion." CEO John Rademacher added: "We are confident in the guidance we are putting forth and look forward to continuing our track record of execution." Two months later, the company disclosed that FY 2026 revenue would instead fall in the range of $5.675 billion to $5.775 billion -- a reduction of approximately $125 million to $225 million from the previously reaffirmed range.
The investigation is examining the period during which these statements were made and whether investors were adequately informed of the factors -- including a significant increased headwind from the change in patient census, “where [management] had assumed the number of Stelara patients converting to some other therapy … and that didn’t happen.”
If you purchased Option Care Health shares and suffered a loss, click here to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the OPCH Investigation
Q: What is the OPCH securities fraud investigation about? A: A securities fraud investigation has been initiated concerning Option Care Health (NASDAQ: OPCH) regarding potentially materially false and misleading statements about the company's financial outlook. Shares fell more than 25% after the company disclosed a Q1 2026 revenue miss and a substantial downward revision to FY 2026 guidance, causing significant losses for shareholders.
Q: Who is conducting the OPCH investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud on behalf of investors who purchased OPCH securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: Who is eligible to participate in the OPCH investigation? A: Investors who purchased OPCH stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do OPCH investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What if I already sold my OPCH shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OPCH and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Why should investors choose Levi & Korsinsky? A: Ranked among top securities litigation firms by ISS for seven consecutive years. Recovered hundreds of millions for shareholders with extensive federal court experience.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On the earnings call, the Company’s guidance included a disclosed Stelara biosimilar gross-profit headwind of $25 million to $35 million for FY 2026. The Company also gave full year 2026 revenue guidance of $5.8B-$6.0B. CEO John Rademacher stated: “We are confident in the guidance we are putting forth and look forward to continuing our track record of execution.”
On April 30, 2026, Option Care Health released its first quarter 2026 financial results, including revenue of only $1.35 billion (a 1.3% increase year over year) missing consensus estimates, as well as net income of $45.3 million, down 3.0% year over year, and an adjusted EBITDA of $104.8 million, down 6.3% year over year. The Company also lowered its full year 2026 guidance for revenue from $5.8B-$6.0B to $5.675B - $5.775B. The Company blamed its reduced guidance on “lower CID patient retention and therapy mix.” On this news, the price of Option Care Health shares declined by $6.54 per share, or approximately 24%, from $26.87 per share on April 29, 2026 to close at $20.33 on April 30, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Option Care Health securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Option Care Health, Inc. (NASDAQ: OPCH) resulting from allegations that Option Care Health, Inc. may have issued materially misleading business information to the investing public. So What: If you purchased Option Care Health, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs.
Boston, Massachusetts--(Newsfile Corp. - May 18, 2026) - Block & Leviton is investigating Option Care Health, Inc. (NASDAQ: OPCH) for potential securities law violations. Investors who have lost money in their Option Care Health, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/opch.
What is this all about?
Option Care Health, Inc.'s stock fell over 30% on April 30, 2026, after the company reported first quarter results and cut its full year revenue guidance. The company attributed the weaker revenue outlook to a larger than expected patient census reset in its chronic inflammatory disease portfolio, including Stelara biosimilar conversions. Earlier in 2026, Option Care Health maintained its full year revenue guidance and said its related patient census assumptions were aligned with expectations.
Who is eligible?
Anyone who purchased Option Care Health, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510.
Whistleblower?
If you have non-public information about Option Care Health, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions.
This notice may constitute attorney advertising.
CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (888) 256-2510
Email: [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297823
Source: Block & Leviton LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On the earnings c.
Option Care Health shares lose more than 25% on April 30, 2026, after Q1 2026 revenue falls short of Wall Street expectations and the Company cuts full-year guidance.
, /PRNewswire/ -- Investors who held Option Care Health (NASDAQ: OPCH) shares saw the stock drop 25%-30% after the Company reported Q1 2026 revenue that missed consensus estimates and slashed its FY 2026 revenue outlook from $5.8 billion-$6.0 billion down to $5.675 billion-$5.775 billion. Shareholders who lost money on OPCH are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
The Q1 2026 earnings report revealed a revenue shortfall against analyst expectations. The Company simultaneously reduced its FY 2026 revenue guidance by up to 3.75% -- a cut of as much as $225 million from the top end of its prior range. The revised outlook of $5.675 billion-$5.775 billion represented a sharp departure from the $5.8 billion-$6.0 billion range that CEO John Rademacher and CFO Meenal Sethna had reaffirmed just 65 days earlier on the Q4 2025 earnings call on February 24, 2026.
The Company cited increased headwinds from the Stelara biosimilar conversion as a contributing factor. On February 24, 2026, CFO Sethna had quantified this headwind at $25 million-$35 million for FY 2026. By April 30, the headwind had increased to $55 million, as "the number of Stelara patients converting to some other therapy" was below expectations, leading to a drop in census and revenue expectations. The projected "400 basis point revenue growth headwind" had quickly jumped to "600 basis points" of CID portfolio headwinds.
If you purchased Option Care Health shares and suffered a loss, click here to discuss your legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities investigations and actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the OPCH Investigation
Q: How much did OPCH stock drop? A: Shares fell over 25% on April 30, 2026, after the Company reported a Q1 revenue miss and cut FY 2026 revenue guidance by up to 3.75%. Investors who purchased shares at higher prices may be entitled to recovery.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Option Care Health made materially false or misleading statements regarding its FY 2026 revenue outlook and the adequacy of its disclosed headwinds. When actual results diverged sharply from prior guidance, the stock price declined significantly.
Q: Who is eligible to participate in the OPCH investigation? A: Investors who purchased OPCH stock and suffered financial losses may be eligible. Eligibility is based on purchase history and documented losses -- not on whether you still hold the shares.
Q: What do OPCH investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What if I already sold my OPCH shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OPCH and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Has Levi & Korsinsky handled similar cases before? A: Yes, including securities investigations involving revenue guidance revisions, earnings misrepresentation, and executive misconduct across numerous industries.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected] \
Tel: (212) 363-7500\
Fax: (212) 363-7171
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON OPTION CARE HEALTH, INC. (OPCH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On April 30, 2026, Option Care Health released.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN OPTION CARE HEALTH, INC. (OPCH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss.
Law Offices of Howard G. Smith continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN OPTION CARE HEALTH, INC. (OPCH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On April 30, 2026, Option Care Health released its first quarter 2026 financial results, including revenue of only $1.35 billion (a 1.3% increase year over year) missing consensus estimates, as well as net income of $45.3 million, down 3.0% year over year, and an adjusted EBITDA of $104.8 million, down 6.3% year over year. The Company also lowered its full year 2026 guidance for revenue by approximately $200 million at the mid-point.
On this news, Option Care Health’s stock price fell $6.54, or 24.3%, to close at $20.33 per share on April 30, 2026, thereby injuring investors.
Contact Us To Participate or Learn More:
If you purchased Option Care Health securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520900817/en/
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON OPTION CARE HEALTH, INC. (OPCH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On April 30.
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On February 24, 2026, Option Care Health announced fourth quarter 2025 earnings. On the earnings call, the Company’s guidance included a disclosed Stelara biosimilar gross-profit headwind of $25 million to $35 million for FY 2026. The Company also gave full year 2026 revenue guidance of $5.8B-$6.0B. CEO John Rademacher stated: “We are confident in the guidance we are putting forth and look forward to continuing our track record of execution.”
On April 30, 2026, Option Care Health released its first quarter 2026 financial results, including revenue of only $1.35 billion (a 1.3% increase year over year) missing consensus estimates, as well as net income of $45.3 million, down 3.0% year over year, and an adjusted EBITDA of $104.8 million, down 6.3% year over year. The Company also lowered its full year 2026 guidance for revenue from $5.8B-$6.0B to $5.675B - $5.775B. The Company blamed its reduced guidance on “lower CID patient retention and therapy mix.” On this news, the price of Option Care Health shares declined by $6.54 per share, or approximately 24%, from $26.87 per share on April 29, 2026 to close at $20.33 on April 30, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired Option Care Health securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
On May 29, 2026, Option Care Health Inc OPCH shares fell 3.2%, closing at $20.88. The stock has seen considerable volatility over the past year, with a 52-week high of $36.80 and a low of $18.01.
GF Value™ verdict: Currently priced at $20.88, OPCH is estimated to be 47.9% undervalued compared to its GF Value™ of $40.10. GF Score™ of 81/100 indicates a strong overall ranking, suggesting solid potential for long-term returns. Notable insider activity, with insiders purchasing $1.9 million worth of shares in the last three months, indicating confidence in the company's future. Is OPCH Overvalued or Undervalued? With a GF Value™ of $40.10, Option Care Health Inc OPCH is significantly undervalued at its current price of $20.88. This represents a substantial margin of safety of 47.9%, indicating a potential opportunity for investors. The GF Valuation label suggests that the stock is not only undervalued but also presents a favorable entry point, assuming the company's fundamentals support future growth. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
Despite the attractive valuation, it is essential to consider the risks involved. The stock has experienced significant declines in recent months, with a year-to-date drop of 34.5%. This downward momentum may deter some investors; however, the underlying value indicated by GF Value™ suggests a divergence between market perception and intrinsic worth.
How Does OPCH's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 16.2x 26.6x Forward P/E 11.4x N/A The current P/E (TTM) of 16.2x is significantly below its 5-year median P/E of 26.6x, indicating that the stock is trading at a valuation that is 39% lower than its historical average. This P/E analysis aligns with the GF Value™ verdict, further reinforcing the notion that OPCH is undervalued compared to its historical trading patterns and future earnings potential.
What Does OPCH's GF Score™ Tell Us? Metric Rating GF Score™ 81/100 Financial Strength 6/10 Profitability 7/10 Growth 9/10 Valuation 4/10 Momentum 4/10 The GF Score™ of 81/100 indicates a robust overall assessment of Option Care Health Inc OPCH , with strong growth potential (9/10) being its standout feature. However, the valuation rank of 4/10 suggests some concerns regarding its current pricing relative to earnings. The financial strength of 6/10 and profitability rank of 7/10 indicate a stable financial position, but the lower momentum rank may reflect recent market performance challenges.
What Are Insiders Doing with OPCH Stock? In the past three months, insiders have demonstrated confidence in Option Care Health Inc by purchasing $1.9 million worth of shares, with no recorded sales. This pattern of insider buying can be a positive signal, suggesting that those with the most intimate knowledge of the company believe in its future prospects. Such actions often reflect a belief in the underlying value and potential for recovery or growth, despite the current market pressures.
What This Means for Investors Based on the GF Value™ assessment indicating that OPCH is 47.9% undervalued, the stock presents a potential opportunity for investors looking for value plays in the healthcare sector. However, the recent price performance and market volatility warrant a cautious approach, considering the risks inherent in the current market environment.
For the complete analysis, visit the Option Care Health Inc OPCH stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is OPCH's GF Score™?
OPCH's GF Score™ is 81/100, indicating a strong overall ranking that suggests solid potential for long-term returns based on key performance metrics.
Is OPCH overvalued or undervalued?
According to the GF Value™ assessment, OPCH is undervalued at its current price of $20.88, which is significantly below its estimated fair value of $40.10.
What is OPCH's P/E ratio?
OPCH has a P/E (TTM) of 16.2x, which is considerably lower than its 5-year median P/E of 26.6x, confirming that the stock is trading at a lower valuation than its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
June 01, 2026 07:00 ET | Source: Option Care Health, Inc.
BANNOCKBURN, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Option Care Health is proud to announce it has been ranked No. 15 on the World’s Most Impactful Companies 2026 list, a global recognition of organizations delivering measurable positive impact across society, the environment, and the economy. This recognition is presented by TIME and Statista, global leaders in data analysis and industry benchmarking, and it can now be viewed on time.com.
Being named to the World’s Most Impactful Companies 2026 list signifies that Option Care Health stands among a select group of organizations driving meaningful change through their core business activities. Unlike perception-based assessments or self-reported sustainability claims, this ranking is grounded in a rigorous, science-based methodology. The Upright Project’s Net Impact Model evaluates companies based on the net-positive contributions of their products and services across four key dimensions: Society, Knowledge, Health, and Environment.
Inclusion in this ranking represents an independent, third-party endorsement of Option Care Health’s measurable impact, reinforcing its commitment to responsible business practices and strengthening trust among customers, team members, partners, and the broader public. It highlights the company’s ability to create value not only for shareholders, but for society at large.
John C. Rademacher, President and CEO of Option Care Health, shared, “Our purpose is to provide extraordinary care that changes lives. That commitment drives everything we do from supporting our patients to shaping the future of healthcare. We’re incredibly proud to be recognized as #15 on TIME's World’s Most Impactful Companies list. This recognition reflects the meaningful impact our team members make every day. We never lose sight of the fact that behind every dose dispensed and every nursing visit is a loved one and we’re honored to make a difference when it matters most.”
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
June 04, 2026 07:00 ET | Source: Option Care Health, Inc.
BANNOCKBURN, Ill., June 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced the appointment of Robert Okunski as Vice President, Investor Relations effective May 26, 2026.
In this role, Okunski will lead the Company’s investor relations strategy and serve as the primary liaison between Option Care Health and the investment community. He will be responsible for communicating the Company’s business strategy, financial performance, capital allocation priorities and long-term growth opportunities to investors, analysts and other key stakeholders.
“Bob brings more than two decades of investor relations leadership experience across healthcare, technology and energy industries,” said Meenal Sethna, Chief Financial Officer of Option Care Health. “His proven track record of building best-in-class investor relations programs, strengthening investor engagement and enhancing transparency, elevating corporate visibility, will be invaluable as we continue to execute our growth strategy and create long-term shareholder value.”
Okunski joins Option Care Health from Enhabit Home Health & Hospice, where he served as Vice President of Investor Relations. During his tenure, he led the company’s investor relations strategy, enhanced engagement with institutional investors and analysts, and increased the company’s visibility within the investment community.
Prior to Enhabit, Okunski held senior investor relations leadership positions at Velo3D Inc., SunPower Corporation, Spansion Inc. and PeopleSoft.
Okunski holds a Master of Business Administration from Moravian University and a Bachelor of Arts from Colgate University.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
